-
Mashup Score: 1
Analysis of 260K tumors IDs copy-number signatures and a HRD biomarker predictive of PARPi response.
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8Newly Diagnosed and Relapsed Epithelial Ovarian Cancer - 9 month(s) ago
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ESMO Clinical Practice Guideline on #EpithelialOvarianCancer: up-to-date recommendations on genomic & biomarker testing, & updated algorithms w/ latest on maintenance tx w/ #PARPi & anti-angiogenic tx, at 1st-line & recurrent. https://t.co/n484KYCBvx #OvarianCancer #GYNSM https://t.co/DSrECmZiB0
-
-
Mashup Score: 3
Objective To evaluate the risk of interstitial lung disease associated with poly (ADP-ribose) polymerase inhibitors (PARPi) and characterize its clinical features. Methods We systematically reviewed phase III randomized clinical trials of interstitial lung disease related to PARPi and calculated Peto odds ratios (ORs) with 95% confidence intervals (CIs). Pharmacovigilance studies were conducted by collecting cases of PARPi-related interstitial lung disease from the FDA Adverse Events Reporting System and assessing disproportionalities by reporting ORs and information components. Results A total of five randomized clinical trials involving 2980 patients were included. Although PARPi showed a tendency to increase the risk of interstitial lung disease compared with controls, this difference was not significant (Peto OR: 4.92; 95% CI: 0.92 to 26.35). A total of 170 cases of interstitial lung disease related to PARPi were included, with a median latency of 99 days. PARPi had a significantly
Source: ijgc.bmj.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @IJGConline: #Interstitial #lung disease in patients treated with #PARPi by Zhichao He 🔗 https://t.co/Xu0JwbR3SB @pedroramirezMD @HsuMd…
-
-
Mashup Score: 2Early Trial Results Show Potential Benefits of FGFR Inhibitors and PARP/ATR Inhibitor Combinations in Multiple Tumor Types - The ASCO Post - 1 year(s) ago
By The ASCO Post Staff Posted: 4/21/2023 2:20:00 PM Last Updated: 4/21/2023 2:41:40 PM In three new clinical trials, researchers have found that the novel fibroblast growth factor receptor (FGFR) inhibitor pemigatinib and new poly (ADP ribose) polymerase (PARP)/ataxia telangiectasia and Rad3-related (ATR)…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Intriguing, preliminary results--with some good responses reported--in early-phase trials of combinations of targeted drugs against refractory cancers, @ASCOPost https://t.co/nFrdunQ8T6 #PrecisionOncology #PARPi #FGFR #ATR #AACR23
-
-
Mashup Score: 1Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary - 1 year(s) ago
Ovarian cancer is the most common cause of mortality in patients with gynecologic malignancies. Advanced-stage high-grade serous carcinoma accounts for most ovarian cancer cases. Current issues in the management of patients with newly diagnosed advanced-stage high-grade serous ovarian cancer include decisions on primary versus interval cytoreduction, hyperthermic intraperitoneal chemotherapy,…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#HGSOC Review @DrCourtneyPenn: Evidence & guidelines for the management of pts with newly diagnosed advanced-stage high-grade serous #ovariancancer #HGSC including cytoreduction, #HIPEC, chemo, bevacizumab, genetic testing & #ParpI are discussed. https://t.co/1H4FH9OhDX https://t.co/pbgSE6b9cP
-
-
Mashup Score: 2The Evolving Landscape of Pancreatic Cancer - 1 year(s) ago
commentary on evolving landscape of pancreatic cancer #JOP
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Pancreaticcancer tx has made some progress, but many challenges remain. Our goals should be to address unmet needs to optimize periop chemo and use #immunotherapy and targeted 🎯 agents like #ParpI for #pancsm wisely. https://t.co/i9gSMnEU7c @MridulaKrishnan
-
-
Mashup Score: 0
PURPOSE Cediranib, a pan-vascular endothelial growth factor receptor inhibitor, suppresses expression of homologous recombination repair (HRR) genes and increases sensitivity to poly-(ADP-ribose) polymerase inhibition in preclinical models. We investigated whether cediranib combined with olaparib improves the clinical outcomes of patients with prostate cancer. METHODS Patients with progressive…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Olaparib (#PARPi) combined with cediranib improved median radiographic PFS compared to olaparib alone in metastatic castrate-resistant #ProstateCancer 👉 https://t.co/guuQ0QQwfL #JCO #PCSM @Joseph_W_Kim https://t.co/jr3GHHrndM
-
-
Mashup Score: 0
Telli and colleagues present a phase II clinical trial of the PARP inhibitor talazoparib in patients with solid tumors and show that the drug has activity in patients with breast cancer with mutations in other homologous recombination pathway genes beyond BRCA1 and BRCA2.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Precision Oncology? In a small clinical trial of #talazoparib, all patients with germline mutations in #PALB2 had treatment-associated tumor regression, @joshuagruber & colleagues @NatureCancer https://t.co/ECfQMGl63A #PARPi https://t.co/fbK5PVe0sj
-
-
Mashup Score: 0
Telli and colleagues present a phase II clinical trial of the PARP inhibitor talazoparib in patients with solid tumors and show that the drug has activity in patients with breast cancer with mutations in other homologous recombination pathway genes beyond BRCA1 and BRCA2.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Finally online in @NatureCancer phase II data showing the clinical activity of single agent #talazoparib in patients without germline #BRCA PVs but with other defects in homologous recombination genes like germline #PALB2 PVs @OncoAlert #PARPi #bcsm Link: https://t.co/aOaJsfFxu1 https://t.co/jaqTxix19m
-
-
Mashup Score: 2Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance - 2 year(s) ago
Objective The benefit of surgery and maintenance treatment with PARP inhibitors (PARPi) has been clearly demonstrated in ovarian cancer. Also, the efficacy and safety of stereotactic body radiotherapy has been shown in patients with metastatic, persistent, and recurrent disease. The aim of this study is to evaluate the management of oligometastatic progression during PARPi maintenance…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @IJGConline: "Management of oligometastatic #ovariancancer recurrence during #PARPi maintenance" https://t.co/t077GrvNtj @GynMe4 @OncoA…
-
Interesting article with a new assay that may better help us predict who benefits from #PARPi. #bcsm #gyncsm Pan-Cancer Analysis of Copy-Number Features Identifies Signatures and a Homologous Recombination Deficiency Biomarker to Predict PARP Response https://t.co/D0pK4TwdrL